Table 2.
Comparison of basic characteristics of Turkish and Azerbaijan patients.
| Turkey | Azerbaijan | |||
|---|---|---|---|---|
| Male-Female | 39.80% Male (n=408) |
60.19% Female (n=617) |
51.75% Male (n=103) |
48.24% Female (n=96) |
| Age [Mean±Std. Dev.(Max-Min)] | 61.85±12.72 (88–18) | 42.71±14.12 (77–17) | ||
| HCV RNA Before the Treatment (Copy/mL) [Mean ± Std. Dev.(Max-Min)] | 6.61×106±1.80×107 (2.6×108–59.4) | 6.50×106±1.65×107 (9.6 × 107–2.2 × 104) | ||
| Genotype Distribution in Turkey | SVR in Turkey | Genotype Distribution | SVR in Azerbaijan | |
| Genotype 1 | 93.26% | 97.69% (n=956) non-responder: n=8; n=14 ex |
83.91% | 98.20% (n=167) non-responder:n=3 |
| Genotype 2 | 2.92% | 90% n=30; n=3 ex | 2.51% | 100% (n=5) |
| Genotype 3 | 1.36% | 100% (n=14) | 13.56% | 96.29% (n=27) non-responder:n=1 |
| Genotype 4 | 2.04% | 100% (n=21) | - | - |
| Genotype 1b & 4 | 0.29% | 100% (n=3) | - | - |
| Genotype 1 & 2 & 3 | 0.09% | 100% (n=1) | - | - |
Legend: Std. Dev.: Standard deviation; SVR: Sustaied Virological Response; ex: Exitus